“The real-world success of our customer, with over 100 OpenBIO units and the incorporation of PAT technologies, is a testament to the platform’s transformative impact.”
Joseph Bravo
In the dynamic landscape of life sciences, the evolution of bioreactor control platforms plays a pivotal role in shaping the future of biopharmaceutical development. Among the frontrunners, the Catalyx OpenBIO Product Family stands out by seamlessly integrating Fed Batch and Perfusion strategies with advanced recipe control functionality. This unique combination not only propels efficiency and precision in the bioprocessing workflow but also provides life science customers with a distinct advantage over the competition. This article delves into the groundbreaking features of OpenBIO, highlighting its real-world impact and how it empowers life science companies to achieve unparalleled advancements.
Fed Batch and Perfusion Integration:
OpenBIO’s prowess lies in its ability to seamlessly integrate both Fed Batch and Perfusion strategies within a single, cohesive platform. This dual capability allows for a versatile approach to bioprocessing, accommodating a wide range of production needs. The Fed Batch strategy facilitates extended production times and higher cell densities, while Perfusion ensures continuous nutrient supply, minimizing metabolic stress and waste accumulation. This is why every OpenBIO unit is equipped to execute these processes, showcasing its capability to seamlessly integrate two of the most common Cell Culture strategies in a single, unified platform.
Recipe Control Functionality:
At the heart of OpenBIO’s capabilities is its advanced recipe control functionality. This feature allows users to precisely define and control process parameters, ensuring a reproducible and optimized bioprocessing environment. The platform’s recipe control functionality contributes to the consistency, scalability, and quality assurance of the biomanufacturing process. This level of control is a game-changer for life science companies striving for excellence in product development.
Real-World Examples:
A testament to OpenBIO’s real-world impact is its adoption by a leading life science customer. With over 100 OpenBIO units deployed across their R&D labs, this customer exemplifies the scalability and reliability of the platform. Notably, they are pushing the boundaries of innovation by integrating Process Analytical Technology (PAT) tools, such as Near-Infrared (NIR) spectroscopy and Raman analyzers, into their OpenBIO-driven bioprocessing. This integration creates a fully automated solution, allowing for real-time monitoring and control, and exemplifies the platform’s adaptability to cutting-edge technologies.
Competitive Edge:
The integration of Fed Batch, Perfusion, and recipe control functionality positions OpenBIO as a trailblazer in bioreactor control. Life science companies leveraging OpenBIO gain a clear advantage over the competition by unlocking:
- Optimized Efficiency: The combined strategies streamline processes, reducing production timelines and enhancing overall efficiency.
- Quality Assurance: Recipe control ensures the consistency of product quality, meeting stringent regulatory standards.
- Flexibility and Adaptability: OpenBIO’s versatility accommodates diverse production needs, offering a competitive edge in the rapidly evolving biopharmaceutical landscape.
- Scale-Up Confidence: The platform’s scalability, demonstrated by the extensive deployment in R&D labs, instills confidence in seamless scale-up to larger manufacturing facilities.
OpenBIO’s integration of Fed Batch, Perfusion, and recipe control functionality represents a paradigm shift in bioreactor control platforms. The real-world success of our customer, with over 100 OpenBIO units and the incorporation of PAT technologies, is a testament to the platform’s transformative impact. Life science companies choosing OpenBIO are not just investing in a control system; they are embracing a dynamic solution that propels them to the forefront of innovation. With OpenBIO, the future of biopharmaceutical development is not just within reach—it is being redefined.
Joseph Bravo is a Business Development Manager for Process Controls at Catalyx North America.